Literature DB >> 27471363

Optimal Duration of Coronary Ligation and Reperfusion for Reperfusion Injury Study in a Rat Model.

Shih-Tai Chang1, Chi-Ming Chu2, Teng-Yao Yang1, Li-Man Hung3, Kuo-Li Pan1, Wen-Jin Cherng4.   

Abstract

BACKGROUND: Reperfusion injury (RI) has an important impact on the clinical prognosis for patients with acute myocardial injury who had their coronary blood flow reestablished. However, no studies to date have investigated the timeframe of coronary occlusion and reperfusion effects on RI.
METHODS: A total of 100 rats were divided into 4 groups based on the coronary ligation period: 30, 60, 120, and 180 min, and each group was further divided into 5 subgroups with different reperfusion periods: 0, 30, 60, 120, and 180 min. R0 was the baseline of each subgroup. All animals received the same protocols for designed ligation and reperfusion periods. Evans blue and 2,3,5-triphenyltetrazolium chloride were used to distinguish different myocardial injury areas: area at risk (AAR) and myocardial necrosis. The differences of the ratios of the necrotic area to AAR between each subgroup and baseline were further averaged to calculate an overall value of each heart.
RESULTS: The relative RI percentages showed significant differences (0.8 ± 2.3%, 4.9 ± 3.3%, 10.8 ± 3.1%, and 20.3 ± 3.6% respectively, p < 0.001) at different time points of reperfusion but not at different time points of ligation (p = 0.593). The effects of different time courses in RI showed that the L120R180 group (43.4 ± 2.3%) had the highest RI difference with the baseline group.
CONCLUSIONS: Maximal RI occurred at the timeframe of L120R180 in our animal model. This result may be utilized to assess the substantial benefits of RI therapies in an experimental rat model setting.

Entities:  

Keywords:  Acute myocardial infarction (AMI); Coronary artery disease (CAD); Primary coronary intervention; Reperfusion injury (RI)

Year:  2016        PMID: 27471363      PMCID: PMC4963426          DOI: 10.6515/acs20150824b

Source DB:  PubMed          Journal:  Acta Cardiol Sin        ISSN: 1011-6842            Impact factor:   2.672


  26 in total

1.  Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial.

Authors:  Paul W Armstrong; Christopher B Granger; Peter X Adams; Christian Hamm; David Holmes; William W O'Neill; Thomas G Todaro; Alec Vahanian; Frans Van de Werf
Journal:  JAMA       Date:  2007-01-03       Impact factor: 56.272

2.  7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1.

Authors:  D I Simon; H Xu; S Ortlepp; C Rogers; N K Rao
Journal:  Arterioscler Thromb Vasc Biol       Date:  1997-03       Impact factor: 8.311

3.  Recovery of the heart after normothermic ischemia. Part II: Myocardial function during postischemic reperfusion.

Authors:  J Mulch; J Schaper; M Gottwik; F W Hehrlein
Journal:  Thorac Cardiovasc Surg       Date:  1979-06       Impact factor: 1.827

Review 4.  Leukocyte-endothelial interactions: clinical trials of anti-adhesion therapy.

Authors:  John M Harlan; Robert K Winn
Journal:  Crit Care Med       Date:  2002-05       Impact factor: 7.598

5.  Intracoronary adenosine administration during reperfusion following 3 hours of ischemia: effects on infarct size, ventricular function, and regional myocardial blood flow.

Authors:  D G Babbitt; R Virmani; H D Vildibill; E D Norton; M B Forman
Journal:  Am Heart J       Date:  1990-10       Impact factor: 4.749

6.  Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study.

Authors:  C J Murray; A D Lopez
Journal:  Lancet       Date:  1997-05-24       Impact factor: 79.321

7.  Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction.

Authors:  H D White; R M Norris; M A Brown; M Takayama; A Maslowski; N M Bass; J A Ormiston; T Whitlock
Journal:  N Engl J Med       Date:  1987-10-01       Impact factor: 91.245

8.  Early thrombolysis in acute myocardial infarction: limitation of infarct size and improved survival.

Authors:  M L Simoons; P W Serruys; M van den Brand; J Res; F W Verheugt; X H Krauss; W J Remme; F Bär; C de Zwaan; A van der Laarse
Journal:  J Am Coll Cardiol       Date:  1986-04       Impact factor: 24.094

9.  Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial.

Authors:  Christopher B Granger; Kenneth W Mahaffey; W Douglas Weaver; Pierre Theroux; Judith S Hochman; Thomas G Filloon; Scott Rollins; Thomas G Todaro; Jose C Nicolau; Witold Ruzyllo; Paul W Armstrong
Journal:  Circulation       Date:  2003-08-18       Impact factor: 29.690

10.  The effect of coronary artery reperfusion on the extent of myocardial infarction.

Authors:  A Deloche; J N Fabiani; J P Camilleri; J Relland; D Joseph; A Carpentier; C Dubost
Journal:  Am Heart J       Date:  1977-03       Impact factor: 4.749

View more
  1 in total

1.  Melatonin Protects Against Hypoxia/Reoxygenation-Induced Dysfunction of Human Umbilical Vein Endothelial Cells Through Inhibiting Reactive Oxygen Species Generation.

Authors:  Shuo Zhao; Yueyuan Wang; Xiaoying Zhang; Lu Zheng; Bin Zhu; Shuang Yao; Ling Yang; Jun Du
Journal:  Acta Cardiol Sin       Date:  2018-09       Impact factor: 2.672

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.